3655 NOBEL DRIVE, SAN DIEGO, CA
Investor Presentation
Other Events
Interim Phase 3 Results Support Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive
News, Material Contracts
Reg. FD
Reports First Quarter 2025 Financial Results and Provides Company Update
Q1
FY 2024
Q2
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence